Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -584.65% is 83% below its 5-year average of -319.72%, near the low end of its 5-year range (-679.59%–-58.31%).
As of the fiscal period ended Tuesday, June 30, 2026. 75.01% below its 12-month average of -334.07%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -584.65%.
RETURN ON EQUITY (ROE)
-584.65%
RETURN ON EQUITY (ROE) AVG TTM
-334.07%
RETURN ON EQUITY (ROE) AVG 3Y
-377.66%
RETURN ON EQUITY (ROE) AVG 5Y
-319.72%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-75.01%
CURRENT VS 3Y AVG
-54.81%
CURRENT VS 5Y AVG
-82.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 741 covered companies
CURRENT VS SECTOR MEDIAN
-1291.70%
vs the sector median at left
PolyPid Ltd.
Market Cap
$98.66M
Return on Equity (ROE)
-584.65%
TTM Avg
-334.07%
3Y Avg
-377.66%
5Y Avg
-319.72%
Market Cap
$97.40M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$97.39M
Return on Equity (ROE)
-461.14%
TTM Avg
-233.39%
3Y Avg
-227.67%
5Y Avg
-163.94%
Market Cap
$97.24M
Return on Equity (ROE)
-103.31%
TTM Avg
-140.03%
3Y Avg
-67.31%
5Y Avg
-49.97%
Market Cap
$102.21M
Return on Equity (ROE)
23.96%
TTM Avg
-4.38%
3Y Avg
-11.56%
5Y Avg
6.84%
Market Cap
$103.06M
Return on Equity (ROE)
-34.11%
TTM Avg
-78.33%
3Y Avg
-16.94%
5Y Avg
-8.09%
Market Cap
$103.68M
Return on Equity (ROE)
-62.61%
TTM Avg
-420.52%
3Y Avg
-378.99%
5Y Avg
-378.99%
Market Cap
$104.79M
Return on Equity (ROE)
-72.02%
TTM Avg
-67.42%
3Y Avg
-55.49%
5Y Avg
-62.36%
Market Cap
$92.33M
Return on Equity (ROE)
-11.85%
TTM Avg
-51.56%
3Y Avg
-105.39%
5Y Avg
-105.39%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PolyPid Ltd. (PYPD) | $98.66M | -584.65% | -334.07% | -377.66% | -319.72% |
| Conexeu Sciences Inc. (CNXU)vs › | $97.40M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.39M | -461.14% | -233.39% | -227.67% | -163.94% |
| Korro Bio, Inc. (KRRO)vs › | $97.24M | -103.31% | -140.03% | -67.31% | -49.97% |
| The Joint Corp. (JYNT)vs › | $102.21M | 23.96% | -4.38% | -11.56% | 6.84% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | -34.11% | -78.33% | -16.94% | -8.09% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $103.68M | -62.61% | -420.52% | -378.99% | -378.99% |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.79M | -72.02% | -67.42% | -55.49% | -62.36% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.33M | -11.85% | -51.56% | -105.39% | -105.39% |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | -116.28% | -71.19% | -41.66% | -29.50% |
ROE
-584.7%
ROA
-206.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -584.65% |
| 2026-03-31 | -383.02% |
| 2025-12-31 | -311.39% |
| 2025-09-30 | -222.69% |
| 2025-06-30 | -168.61% |
| 2024-12-31 | -377.69% |
| 2024-03-31 | -339.33% |
| 2023-09-30 | -679.59% |
| 2023-06-30 | -331.99% |
| 2023-03-31 | -295.60% |
| 2022-12-31 | -678.08% |
| 2022-09-30 | -404.17% |
| 2022-06-30 | -246.76% |
| 2022-03-31 | -158.74% |
| 2021-12-31 | -118.47% |
| 2021-09-30 | -76.15% |
| 2021-06-30 | -58.31% |
| 2021-03-31 | -60.00% |
| 2020-12-31 | -50.66% |
| 2020-09-30 | -41.88% |
| 2020-06-30 | -34.13% |
| 2020-03-31 | -43.82% |
| 2019-12-31 | -22.32% |
